Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
idronoxil · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| idronoxil | DRUG | - |
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed solid tumor * Refractory to standard therapy OR * No standard therapy exists * No breast cancer * No active CNS metastases * Known CNS metastases must be previously treated with radiotherapy or surgery and stable for at le...
Idronoxil is an investigational small molecule being developed by Kazia Therapeutics Limited (KZIA) for the treatment of unspecified adult solid tumors. It is currently in Phase 1 clinical development, meaning it is still being studied in clinical trials and has not been approved by regulatory authorities.
Idronoxil is being studied for use in unspecified adult solid tumors, as defined by the clinical trial protocol. The drug is intended for patients with refractory solid tumors, meaning tumors that have not responded to prior treatments. It is currently in Phase 1 clinical development.
Idronoxil is being developed by Kazia Therapeutics Limited, an oncology-focused biopharmaceutical company. The company's stock is traded under the ticker symbol KZIA. Kazia is conducting clinical trials to evaluate the safety and efficacy of idronoxil in patients with solid tumors.
Idronoxil is in Phase 1 clinical development. This means the drug is in the early stages of testing in humans, primarily to evaluate its safety, tolerability, and dosing. It is an investigational drug and has not yet been approved by the FDA or other regulatory agencies.
Idronoxil has been studied in one completed Phase 1 clinical trial, identified as NCT00022295. This trial, titled 'Phenoxodiol in Treating Patients With Refractory Solid Tumors,' enrolled 36 adult patients in the United States. The trial was uncontrolled, meaning there was no comparator group, and it was not randomized or double-blinded.
Yes, idronoxil is also known as phenoxodiol. The completed Phase 1 clinical trial NCT00022295 used the name phenoxodiol in its title. This alternative name is important for readers searching for information about the drug under either name.